This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 1982 Jan-Feb;7(1):42-56.

doi: 10.2165/00003088-198207010-00003.

Clinical pharmacokinetics and potentially important drug interactions of sulphinpyrazone

A K Pedersen, P Jakobsen, J P Kampmann, J M Hansen

PMID: 7042172
DOI: 10.2165/00003088-198207010-00003

Review

Clinical pharmacokinetics and potentially important drug interactions of sulphinpyrazone

A K Pedersen et al. Clin Pharmacokinet. 1982 Jan-Feb.

. 1982 Jan-Feb;7(1):42-56.

doi: 10.2165/00003088-198207010-00003.

Authors

A K Pedersen, P Jakobsen, J P Kampmann, J M Hansen

PMID: 7042172
DOI: 10.2165/00003088-198207010-00003

No abstract available

PubMed Disclaimer

Similar articles

Evidence for a dual action of sulphinpyrazone on drug metabolism in man: theophylline-sulphinpyrazone interaction.
Birkett DJ, Miners JO, Attwood J. Birkett DJ, et al. Br J Clin Pharmacol. 1983 May;15(5):567-9. doi: 10.1111/j.1365-2125.1983.tb02093.x. Br J Clin Pharmacol. 1983. PMID: 6860533 Free PMC article.
Pharmacokinetics of sulphinpyrazone and its major metabolites after a single dose and during chronic treatment.
Schlicht F, Staiger C, de Vries J, Gundert-Remy U, Hildebrandt R, Harenberg J, Wang NS, Weber E. Schlicht F, et al. Eur J Clin Pharmacol. 1985;28(1):97-103. doi: 10.1007/BF00635715. Eur J Clin Pharmacol. 1985. PMID: 3987792
A study of the effect of sulphinpyrazone ('Anturan') on blood viscosity.
Johnston RV, Lowe GD, Drummond MM, Forbes CD, Prentice CR. Johnston RV, et al. Curr Med Res Opin. 1979;6(4):271-3. doi: 10.1185/03007997909109436. Curr Med Res Opin. 1979. PMID: 527353 Clinical Trial.
Pharmacology and pharmacokinetics of platelet-active drugs under current clinical investigation.
FitzGerald GA, Sherry S. FitzGerald GA, et al. Adv Prostaglandin Thromboxane Leukot Res. 1982;10:107-72. Adv Prostaglandin Thromboxane Leukot Res. 1982. PMID: 6216780 Review. No abstract available.
Sulfinpyrazone: a review of its pharmacological properties and therapeutic use.
Margulies EH, White AM, Sherry S. Margulies EH, et al. Drugs. 1980 Sep;20(3):179-97. doi: 10.2165/00003495-198020030-00002. Drugs. 1980. PMID: 7000488 Review.

See all similar articles

Cited by

Renal clearance of sulphinpyrazone in man.
Lentjes EG, Russel FG, van Ginneken CA. Lentjes EG, et al. Eur J Clin Pharmacol. 1986;31(4):473-8. doi: 10.1007/BF00613527. Eur J Clin Pharmacol. 1986. PMID: 3816927
Pharmacokinetics and Reversible Biotransformation of Sulfinpyrazone and Its Metabolites in Rabbits. II. Multiple-Dose Study.
Kuo BS, Ritschel WA. Kuo BS, et al. Pharm Res. 1986 Jun;3(3):178-83. doi: 10.1023/A:1016322326443. Pharm Res. 1986. PMID: 24271526
A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?
Lee MH, Graham GG, Williams KM, Day RO. Lee MH, et al. Drug Saf. 2008;31(8):643-65. doi: 10.2165/00002018-200831080-00002. Drug Saf. 2008. PMID: 18636784 Review.
Plasma levels of sulfinpyrazone and of two of its metabolites after a single dose and during the steady state.
Rosenkranz B, Fischer C, Jakobsen P, Kirstein Pedersen A, Frölich JC. Rosenkranz B, et al. Eur J Clin Pharmacol. 1983;24(2):231-5. doi: 10.1007/BF00613823. Eur J Clin Pharmacol. 1983. PMID: 6840173

References

1. Clin Pharmacol Ther. 1979 Nov;26(5):611-7 - PubMed
1. Br J Clin Pharmacol. 1980 Mar;9(3):239-45 - PubMed
1. J Pharmacol Exp Ther. 1957 Mar;119(3):418-26 - PubMed
1. Br Med J (Clin Res Ed). 1981 Apr 25;282(6273):1361-2 - PubMed
1. Eur J Clin Pharmacol. 1978 Jun 19;13(4):263-5 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.